Entinostat (MS-275)

Name: Entinostat (MS-275)
Brand: Selleck Chemicals
SKU: S1053
Rating: 5 (328 reviews)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

328 publications

CAS No. 209783-80-2

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.

Selleck's Entinostat (MS-275) has been cited by 328 publications

Science, 2021, 372(6537)eaba1786

PubMed: 33795428 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Nat Genet, 2020, 10.1038/s41588-020-00729-3

PubMed: 33139953 ( click the link to review the publication )

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Chem Biol, 2021, 10.1038/s41589-021-00772-z

PubMed: 33723432 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2699

PubMed: 33976188 ( click the link to review the publication )

Neuro Oncol, 2021, 23(3):376-386

PubMed: 33130903 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-2357

PubMed: 33994371 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01931-1

PubMed: 34247191 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13060

PubMed: 34258881 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:641987

PubMed: 34041236 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(12):16219-16228

PubMed: 34157682 ( click the link to review the publication )

Mol Neurobiol, 2021, 10.1007/s12035-021-02361-6

PubMed: 33772465 ( click the link to review the publication )

Gynecol Oncol, 2021, S0090-8258(21)00325-5

PubMed: 33867143 ( click the link to review the publication )

J Virol, 2021, JVI0085321

PubMed: 34232065 ( click the link to review the publication )

J Enzyme Inhib Med Chem, 2021, 36(1):34-47

PubMed: 33100043 ( click the link to review the publication )

Genes (Basel), 2021, 12(2)260

PubMed: 33670166 ( click the link to review the publication )
Sci China Life Sci, 2021, 10.1007/s11427-020-1855-4

PubMed: 33420926 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2021, mcs.a006049

PubMed: 33722797 ( click the link to review the publication )

Sci Adv, 2021, 7(9)eabe3348

PubMed: 33637530 ( click the link to review the publication )

Life Sci, 2021, 271:119127

PubMed: 33515561 ( click the link to review the publication )

Nat Protoc, 2020, 15(3):1209-1236

PubMed: 32051612 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(11):e12525

PubMed: 33026191 ( click the link to review the publication )

EMBO Rep, 2020, 4;21(3):e49254

PubMed: 32009295 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

Theranostics, 2020, 10(21):9644-9662

PubMed: 32863951 ( click the link to review the publication )

Elife, 2020, 9e59780

PubMed: 33074102 ( click the link to review the publication )

J Autoimmun, 2020, 108:102379

PubMed: 31883829 ( click the link to review the publication )

J Crohns Colitis, 2020, 14(8):1103-1118

PubMed: 32030401 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0336

PubMed: 32978226 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0756

PubMed: 33334730 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

J Mol Cell Cardiol, 2020, 149:73-81

PubMed: 32971072 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:573820

PubMed: 33195208 ( click the link to review the publication )

Cell Biol Toxicol, 2020, 10.1007/s10565-020-09560-2

PubMed: 33040242 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

J Transl Med, 2020, 7;18(1):159

PubMed: 32264925 ( click the link to review the publication )

Cell Signal, 2020, 70:109573

PubMed: 32087304 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):343-356

PubMed: 31932908 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )
Theranostics, 2020, 10(16):7351-7368

PubMed: 32641996 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

JCI Insight, 2020, 5(4)

PubMed: 32102981 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.202048566

PubMed: 32644192 ( click the link to review the publication )

Mol Psychiatry, 2020, 10.1038/s41380-020-00958-2

PubMed: 33235333 ( click the link to review the publication )

PLoS Biol, 2020, 18(11):e3000981

PubMed: 33253182 ( click the link to review the publication )

Gastroenterology, 2019, 156(1):187-202

PubMed: 30267710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5324

PubMed: 31757943 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz1136

PubMed: 31799598 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(5):1005-1025

PubMed: 30599067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )
Br J Cancer, 2019, 121(12):1039-1049

PubMed: 31690832 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 10:409

PubMed: 30915074 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

J Immunol, 2019, 203(12):3199-3208

PubMed: 31732526 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(4):317-328

PubMed: 30668714 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108570

PubMed: 31054509 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )

J Mol Endocrinol, 2019, 62(2):67-78

PubMed: 30481159 ( click the link to review the publication )

Dev Biol, 2019, 449(2):122-131

PubMed: 30826398 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0213186

PubMed: 30830950 ( click the link to review the publication )
Pain Res Manag, 2019, 2019:1648919

PubMed: 30809320 ( click the link to review the publication )

Oncotarget, 2019, 10(20):1903-1917

PubMed: 30956773 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j.jcmgh.2019.10.005

PubMed: 31654770 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):623

PubMed: 29795376 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Arch Toxicol, 2018, 92(7):2227-2243

PubMed: 29845424 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Oncoimmunology, 2018, 7(11):e1466018

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2018, 1864(8):2610-2622

PubMed: 29684588 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)

PubMed: 30424007 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )
Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9391

PubMed: 29925922 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )

Biochem J, 2018, 475(24):3921-3932

PubMed: 30552170 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194661

PubMed: 29579087 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):1967-1974

PubMed: 30008890 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467324 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Cond Med, 2018, 1(2):64-72

PubMed: 30135960 ( click the link to review the publication )

Oncotarget, 2018, 9(28):19597-19612

PubMed: 29731968 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)E3539

PubMed: 30424007 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

JCI Insight, 2018, 3(4)95824

PubMed: 29467324 ( click the link to review the publication )
Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2235-2248

PubMed: 28436940 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(51):E10981-E10990

PubMed: 29203668 ( click the link to review the publication )

Cell Rep, 2017, 19(4):875-889

PubMed: 28445736 ( click the link to review the publication )

Elife, 2017, 6e22767

PubMed: 28318487 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )

J Med Chem, 2017, 60(13):5334-5348

PubMed: 28581289 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2689-2700

PubMed: 28802253 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2017, 6:54-65

PubMed: 28664166 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Virol, 2017, 91(16)

PubMed: 28566376 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12084

PubMed: 28935977 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8641

PubMed: 28819194 ( click the link to review the publication )
Mech Ageing Dev, 2017, 166:6-15

PubMed: 28843433 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017, 76(12):1000-1007

PubMed: 29136455 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2017, 312(3):F502-F515

PubMed: 28052874 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Int J Mol Med, 2017, 40(3):661-672

PubMed: 28677722 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Oncotarget, 2017, 8(69):114156-114172

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83155-83170

PubMed: 29137331 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4079-4095

PubMed: 27863422 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:375-385

PubMed: 27761836 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371976 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )
Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Sci Signal, 2016, 9(422):ra34

PubMed: 27048565 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:62

PubMed: 27231489 ( click the link to review the publication )

Oncoimmunology, 2016, 5(11):e1219008

PubMed: 27999738 ( click the link to review the publication )

Oncoimmunology, 2016, 5(6):e1164919

PubMed: 27471639 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(2):299-312

PubMed: 26772204 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Dis Model Mech, 2016, 9(5):541-52

PubMed: 26989193 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

J Cell Mol Med, 2016, 20(12):2289-2298

PubMed: 27420561 ( click the link to review the publication )

Front Cell Neurosci, 2016, 10:221

PubMed: 27729849 ( click the link to review the publication )

Front Cell Neurosci, 2016, 9:510

PubMed: 26793062 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )
Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Biol Chem, 2016, 397(1):75-83

PubMed: 26431101 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Gene Regul Syst Bio, 2016, 10:9-13

PubMed: 26823649 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Blood, 2015, 5;125(6):941-8

PubMed: 25468569 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26701908 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )
Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Sci Rep, 2015, 5:16873

PubMed: 26585834 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )

Front Neurosci, 2015, 9:319

PubMed: 26441495 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 151(2):281-94

PubMed: 25904215 ( click the link to review the publication )

Virology, 2015, 485:340-54

PubMed: 26331681 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144660

PubMed: 26713848 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137699

PubMed: 26361334 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )
PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1441-53

PubMed: 24463822 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )

Retrovirology, 2014, 11:67

PubMed: 25116364 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106784

PubMed: 25198282 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4516-28

PubMed: 24980831 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(28):E2621-8

PubMed: 23788661 ( click the link to review the publication )
Genet Mol Biol, 2013, 36(3):299-307

PubMed: 24130434 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2076-86

PubMed: 23047626 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

Pediatr Nephrol, 2013, 28(10):1909-21

PubMed: 23052657 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )
Eur Neuropsychopharmacol, 2012, 22(9):651-6

PubMed: 22341945 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

J Virol, 2012, 86(6):3073-87

PubMed: 22238308 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41776

PubMed: 22848598 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 428(1):121-6

PubMed: 23063976 ( click the link to review the publication )

Biomol Ther (Seoul), 2012, 20(1):81-8

PubMed: 24116279 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

J Biomed Biotechnol, 2011, 2011:371832

PubMed: 21151613 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
SCC-3	NY[wb5l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXPz[ppKUUN3ME2wMlA3OSEQvF2=	M1jpTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
ALL-PO	M{DKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NE\mdJpKSzVyPUCuNFY{PTVizszN	NWn0OXVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
697	NF22OGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml6yTWM2OD1yLkC5PVc3KM7:TR?=	NUPvRlh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H748	NXHLcXRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHXYZY9KSzVyPUCuNVA{OzRizszN	M1vNbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NKM-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUD5NYZwUUN3ME2wMlExQTF{IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ES1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4m0NGlEPTB;MD6xNVI2PSEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1963	MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{LmUWlEPTB;MD6xNVU4QSEQvF2=	M1zXWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H1417	NYD6VGlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1u2[2lEPTB;MD6xNlk4PCEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NEC8	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2Kw[2lEPTB;MD6xN\|UzPyEQvF2=	MoLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
CRO-AP2	NWjHe25jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX;JR\|UxRTBwMU[4PFkh\|ryP	M17Oe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
A3-KAW	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXnXXZE1UUN3ME2wMlE4PjJ5IN88US=>	NUHDNJpGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SF539	NFLkZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGjCRodKSzVyPUCuNVk2QTNizszN	NIXtPYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NOS-1	M2i5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2Dq[mlEPTB;MD6xPVYyQSEQvF2=	MlnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NTERA-S-cl-D1	M{LwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1jHXGlEPTB;MD6yNFEyOyEQvF2=	M1;NOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
COR-L88	M4PLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn;ETWM2OD1yLkKyPVU6KM7:TR?=	MmjkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
EM-2	NWLiSJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXS2UpBsUUN3ME2wMlI1ODd7IN88US=>	M4HuNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KARPAS-45	NVHDdG94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mm\RTWM2OD1yLkK3PFM{KM7:TR?=	M2fpe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
DSH1	MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVPCcopMUUN3ME2wMlI5PzB6IN88US=>	MmfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
HT-144	NU\O[olrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWXnN\|ZPUUN3ME2wMlMxOjV4IN88US=>	NELh[Iw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ATN-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnewTWM2OD1yLkOwOVc3KM7:TR?=	NYizNpo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
HEL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlH5TWM2OD1yLkOxN\|Q5KM7:TR?=	M1vTd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NB12	NUPXWGR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mof5TWM2OD1yLkOxO\|U3KM7:TR?=	NWTqTXk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LU-139	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{f0OGlEPTB;MD6zN\|UyKM7:TR?=	NIfheG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
J-RT3-T3-5	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIfZeo1KSzVyPUCuN\|M4OTZizszN	NW\rXXFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MOLT-13	NUm1[Y9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFT0NXpKSzVyPUCuN\|M5OSEQvF2=	Ml7GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SR	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYPJR\|UxRTBwM{SyOlEh\|ryP	NGjtOWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
CMK	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MU\JR\|UxRTBwM{W3Nlch\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ES8	NInLZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYfJR\|UxRTBwM{[wNlIh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LB647-SCLC	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3vsVWlEPTB;MD6zOlc{KM7:TR?=	MkHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
TE-8	NHuxSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2HkOGlEPTB;MD6zOlk{PSEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
BV-173	NHjNUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MU\JR\|UxRTBwM{exNlEh\|ryP	Ml\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
DEL	NWXNNmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NITkT3NKSzVyPUCuN\|c1QDdizszN	MnjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
ARH-77	NHL6SGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MofRTWM2OD1yLkO4NVk{KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCCIT	NY\wcIRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoXaTWM2OD1yLkO4OlQ6KM7:TR?=	NEX4TlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
RPMI-8402	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV;JR\|UxRTBwM{i3NFEh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MONO-MAC-6	MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGXmS5dKSzVyPUCuN\|g4PzZizszN	NV:4R5V3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SK-MM-2	MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVfJR\|UxRTBwM{m4Olgh\|ryP	NXr1cppSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
CHP-126	NELieWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnjlTWM2OD1yLkSwNlMyKM7:TR?=	NVPXfJJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
A101D	NUHrUWZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXPQT294UUN3ME2wMlQxOyEQvF2=	MoLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SCH	MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnjhTWM2OD1yLkSwN\|QzKM7:TR?=	NXrve253RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NMC-G1	Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmjJTWM2OD1yLkSwN\|Y4KM7:TR?=	M1rGWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H209	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEe4[JhKSzVyPUCuOFA3OTNizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MOLT-16	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MX7JR\|UxRTBwNEGwNVch\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
RPMI-6666	NX;lOXd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVfGZZVPUUN3ME2wMlQyOTJizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
OPM-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFfXeItKSzVyPUCuOFE2OTNizszN	NWjWNFdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MRK-nu-1	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX;PTZZ4UUN3ME2wMlQ{OTV\|IN88US=>	Ml62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
BC-1	NX;YZolMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3SyT2lEPTB;MD60N\|QxOyEQvF2=	M1nRXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MHH-NB-11	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4i2b2lEPTB;MD60N\|Q2OyEQvF2=	MoLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlrWTWM2OD1yLkSzPFk4KM7:TR?=	M1XpVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LS-513	M3The2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWHJR\|UxRTBwNES1NFEh\|ryP	NVnDdXRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
K5	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWPJR\|UxRTBwNEewNlUh\|ryP	MoTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
HOP-62	NFTOO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2TscmlEPTB;MD60PFM2QCEQvF2=	NFjEflY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H187	M2ruXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4nMNmlEPTB;MD60PVIzPyEQvF2=	M4XoNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
BE-13	NIXLOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{Tic2lEPTB;MD60PVY3OSEQvF2=	MofxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
HC-1	Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2C3WmlEPTB;MD61NFQ4OyEQvF2=	NX\4VIZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ACN	NIjldlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXjJR\|UxRTBwNUGwNlgh\|ryP	M{HwWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HCC1599	NV:5NmpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2rqOWlEPTB;MD61NVU4KM7:TR?=	MnzEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MV-4-11	M1vL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIr5T25KSzVyPUCuOVMxPDFizszN	NUPCe4dIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LC-2-ad	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmfSTWM2OD1yLkWzOlY{KM7:TR?=	MlXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
HL-60	NWHnTpE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGL1ZpdKSzVyPUCuOVQzPjFizszN	M1nLO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NB17	M{TQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFniUWNKSzVyPUCuOVQ{QCEQvF2=	NHzGc5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
TE-1	NUS4SGRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{H1T2lEPTB;MD61OVMxPiEQvF2=	NGPjRVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H524	NYDIb\|lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmrOTWM2OD1yLkW1OFAyKM7:TR?=	M2\6U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MZ7-mel	M{m1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYDKT\|NIUUN3ME2wMlU3OTB3IN88US=>	NEjaRpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
L-363	M136ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVnJR\|UxRTBwNU[2OVch\|ryP	NYmwZlhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
BL-41	MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoPWTWM2OD1yLkW2PFg6KM7:TR?=	NHzXTGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LU-134-A	M1;UcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXLJR\|UxRTBwNUewO\|Mh\|ryP	NXW0cI1NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SIG-M5	NEjCPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYPJR\|UxRTBwNUe4OFgh\|ryP	NUPofmV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ONS-76	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1\kWmlEPTB;MD61PFI1OiEQvF2=	NVT5[G9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
KARPAS-299	NVrENIR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYfJR\|UxRTBwNUi1NFQh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
DU-4475	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4HWV2lEPTB;MD61PFcxOyEQvF2=	M2TjO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NB69	MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4XQemlEPTB;MD61PVgzPSEQvF2=	MmPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MHH-PREB-1	Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWG0PIY1UUN3ME2wMlYxPzF7IN88US=>	MkXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LU-165	NXO2[VhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2DXNmlEPTB;MD62NVgyOiEQvF2=	MlXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LOUCY	NIXZN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkHGTWM2OD1yLk[zN\|Y1KM7:TR?=	M3HNVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H526	MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1\aNWlEPTB;MD62N\|U1OSEQvF2=	MoS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
KE-37	NXXDXIlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmDyTWM2OD1yLk[0Nlc3KM7:TR?=	NYC3UnVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NALM-6	M33QVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mm\JTWM2OD1yLk[0PFYh\|ryP	M4K0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
CW-2	M3PwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1zZfWlEPTB;MD62OVc6PCEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SU-DHL-1	M2Lq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmHkTWM2OD1yLk[1PVQ4KM7:TR?=	NGK1TW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NB13	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkfKTWM2OD1yLk[2PFE4KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
QIMR-WIL	MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWrJR\|UxRTBwNkizOFMh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ECC12	M3noWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFy1NGNKSzVyPUCuO\|AxQDZizszN	M1nNNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KALS-1	M1S1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGrKT5hKSzVyPUCuO\|A1QTJizszN	NWfsPWFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
COR-L279	M17mdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFnmOFRKSzVyPUCuO\|A6QTZizszN	NYjhVHBuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB14	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXi2[ldnUUN3ME2wMlczPjF5IN88US=>	NFXkVGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
CCRF-CEM	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXTJR\|UxRTBwN{S2OlEh\|ryP	NEPT[3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SW954	MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX\JR\|UxRTBwN{W5PVkh\|ryP	M37MfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
IST-SL1	NFz0c3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYm0dVNMUUN3ME2wMlc4OzR6IN88US=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LAMA-84	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIi3VYhKSzVyPUCuO\|c2PjdizszN	M4L6UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
Daudi	NF\BV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MorHTWM2OD1yLke3OlgyKM7:TR?=	M17NPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
BC-3	NGe1XG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXTJR\|UxRTBwN{izNFgh\|ryP	NFLNZWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HCC2998	NULCd29oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIDGXoFKSzVyPUCuO\|g{PiEQvF2=	M{X0d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H69	NELwTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml7STWM2OD1yLkiwNVQ4KM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
CPC-N	Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MojRTWM2OD1yLkiwOVI1KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NOMO-1	Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHXFPXhKSzVyPUCuPFExQDRizszN	M1HaUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
CESS	M4nqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4\3[mlEPTB;MD64NVE6PyEQvF2=	M{f0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LC4-1	NUDi[4p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX;JR\|UxRTBwOESwNFch\|ryP	NG\MPXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
BL-70	NYDCR2JzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEjEUIhKSzVyPUCuPFU4ODJizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ES4	NX75SlZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEPucoRKSzVyPUCuPFU5PjhizszN	M2myUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HCE-T	NH7BUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV\T[2RuUUN3ME2wMlg4OTdzIN88US=>	M3PXclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
JAR	Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV\JR\|UxRTBwOEe4Nlch\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ST486	NXT3[IF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEK5No5KSzVyPUCuPFc6OTdizszN	M1HVXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KS-1	M1XZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mo\LTWM2OD1yLki4NFk3KM7:TR?=	M1vPT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
GDM-1	MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGH2U2hKSzVyPUCuPFg3QDdizszN	NX3lb3JMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
EHEB	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH[wS\|JKSzVyPUCuPVI2QDVizszN	M{XJdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LB2518-MEL	M17jN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXTi[lNNUUN3ME2wMlk{Ojh2IN88US=>	M2nIRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
GOTO	M{K2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1XLcGlEPTB;MD65OVA4PiEQvF2=	M{LvZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LXF-289	Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWr1dWpZUUN3ME2wMlk2QTBzIN88US=>	M1XmNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
ES6	NELrUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVfJR\|UxRTBwOU[0N\|ch\|ryP	NVnuS49KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
OS-RC-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3jFbWlEPTB;MD65Olg{KM7:TR?=	NFniN3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
DMS-153	M2jqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4XFXWlEPTB;MD65O\|Q3QSEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SK-PN-DW	MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlXjTWM2OD1yLkm3PFMyKM7:TR?=	NHr2[lI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HH	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MULJR\|UxRTBwOUi5OVkh\|ryP	MkfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SH-4	M4DM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIGwWIVKSzVyPUGuNFI1OSEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MOLT-4	NUTQUo46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH3yb2NKSzVyPUGuNFM1PTRizszN	M1rnb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
TGW	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnrYTWM2OD1zLkC3Olc2KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
L-540	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4TtPGlEPTB;MT6xNFYxPCEQvF2=	M3ztZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
PF-382	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX\vXYR[UUN3ME2xMlEyPTF\|IN88US=>	NIf6WoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LC-1F	NEDNdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGPUe5BKSzVyPUGuNVIxODdizszN	M2S2[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
OVCAR-4	NVzLWXBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NU\6UVVZUUN3ME2xMlE{OTZ3IN88US=>	NGnEWJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
A4-Fuk	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF\BcGRKSzVyPUGuNVU{PjRizszN	NGnMTog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HCC2218	NYK4N3FKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYXtO\|QxUUN3ME2xMlE3PjRzIN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HAL-01	NX;RW4pkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml\sTWM2OD1zLkG2PVQ{KM7:TR?=	NFXQb3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
IST-MEL1	NVTvfHZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2rOUGlEPTB;MT6xO\|Y2QSEQvF2=	MmfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H719	NIrSXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnHTTWM2OD1zLkG3PFk5KM7:TR?=	NVPSdnFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
EVSA-T	M2LhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH7NcJdKSzVyPUGuNVgyOTRizszN	MlnVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SK-NEP-1	NYj3d2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYXWN5VYUUN3ME2xMlIxOjZ4IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
OCUB-M	M{nkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4jwVWlEPTB;MT6yNVQ5QSEQvF2=	NXvuc5h2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MEG-01	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGDjPVlKSzVyPUGuNlIyOThizszN	NYj5XokyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
no-10	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXnJR\|UxRTFwMkOxNVIh\|ryP	M2PuWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MHH-CALL-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWPjeIxjUUN3ME2xMlI1PzJzIN88US=>	NVzVcWh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SK-N-DZ	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYnSVXpYUUN3ME2xMlI1Pzd4IN88US=>	MnP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SCLC-21H	NV7wfZV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH3vZldKSzVyPUGuNlY1PzhizszN	MnSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
CTV-1	NWfFeY5vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoXrTWM2OD1zLkK3OFI2KM7:TR?=	NUnyUYsyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYLJR\|UxRTFwMke3N\|Ih\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H64	M2rKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXnJR\|UxRTFwMki0OlIh\|ryP	NFnFbZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
MDA-MB-134-VI	NInSeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NI\MbIhKSzVyPUGuNlg2PzdizszN	MkewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LB2241-RCC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3Hkc2lEPTB;MT6yPFY3OyEQvF2=	M13udVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
8-MG-BA	MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4PlcmlEPTB;MT6yPFg3PiEQvF2=	NGrzdXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LP-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYTlNnFFUUN3ME2xMlI6QTR5IN88US=>	NFPp[pc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LS-411N	NVqyUlNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml3LTWM2OD1zLkOwPVk5KM7:TR?=	M4LNeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
CAL-148	NVn6ZVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWHJR\|UxRTFwM{K1OFIh\|ryP	M1PVblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H2171	M3LLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYrLT5pZUUN3ME2xMlM1PTB{IN88US=>	NFjvZWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
JiyoyeP-2003	NF\LUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUXiRXJVUUN3ME2xMlM2OzlizszN	M4n4e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H2107	NHS4XWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2GyXGlEPTB;MT6zOVg5OyEQvF2=	NHToToM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
BB30-HNC	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{PuSGlEPTB;MT6zPFk4QCEQvF2=	NGnRVXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
K-562	NF\iWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmjGTWM2OD1zLkO5NlE6KM7:TR?=	MorEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
PSN1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHLI[ZZKSzVyPUGuOFIzQDdizszN	NX7zdnJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
HCC2157	M{CxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGfYOmVKSzVyPUGuOFI3QTFizszN	NEXyWFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SBC-1	MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH[x[\|VKSzVyPUGuOFI4PDFizszN	NIHVZ5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
MC116	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXThfYk5UUN3ME2xMlQ{PjF3IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
KARPAS-422	NITVbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVy4XoNPUUN3ME2xMlQ2OzV6IN88US=>	NYOyT3lXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LB996-RCC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NY\ONZZkUUN3ME2xMlQ4OTB\|IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MSTO-211H	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVTJR\|UxRTFwNEe5PFch\|ryP	NH64d4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
BT-474	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4WzTGlEPTB;MT61NVc3PCEQvF2=	NE\lS\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
A388	M3H2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXfrVFFrUUN3ME2xMlUyQTR3IN88US=>	NIP2dW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SJSA-1	M17qNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmrrTWM2OD1zLkWyNlYh\|ryP	Moq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
COLO-829	M4Hqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3fzZ2lEPTB;MT61N\|U3PCEQvF2=	NHPwbGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KM-H2	M{npNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4rR[GlEPTB;MT61OlY4KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
GR-ST	NEC1RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYTJR\|UxRTFwNU[4NkDPxE1?	MoW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
RPMI-8866	MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoqyTWM2OD1zLk[wNVQ1KM7:TR?=	NHfDfHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KG-1	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn;MTWM2OD1zLk[xPVAyKM7:TR?=	MojpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H82	NWDUfmY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGC1NlZKSzVyPUGuOlM1ODZizszN	NV21XXZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LB1047-RCC	NGO3S2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV7JR\|UxRTFwNkO0OVkh\|ryP	M3rweVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KM12	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlHqTWM2OD1zLk[0O{DPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NB5	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmHBTWM2OD1zLk[1Olc4KM7:TR?=	NID4XYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HDLM-2	MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2m1[mlEPTB;MT62PFI5OSEQvF2=	M1PtXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KU812	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3PnPWlEPTB;MT62PVYxPSEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
DB	MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWLpcFFnUUN3ME2xMlcxOzV\|IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HD-MY-Z	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnOwTWM2OD1zLke1NlM1KM7:TR?=	NIK2WGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KURAMOCHI	NFf4[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NG\DU3lKSzVyPUGuO\|czODdizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ETK-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXLJR\|UxRTFwN{i4O\|kh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SK-UT-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NELwbpBKSzVyPUGuO\|k{QDhizszN	Mnf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
HUTU-80	M2nrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NG\CeYxKSzVyPUGuO\|k2ODhizszN	NXTC[Y5KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ES7	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Ml\jTWM2OD1zLkiwN\|AzKM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SW872	M1u2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MofnTWM2OD1zLkixN\|k2KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
TK10	M1LLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVTJR\|UxRTFwOEOxNFgh\|ryP	M1jQ[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LB831-BLC	NYn0VYZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUPJR\|UxRTFwOEO1OlMh\|ryP	M4XW[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
TE-9	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXn0c2tVUUN3ME2xMlg1PDJ{IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MLMA	M4HFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUfpSI1SUUN3ME2xMlg5OjN2IN88US=>	NUSyeGNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
D-542MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{DDdWlEPTB;MT64PVM4OyEQvF2=	M4Ds[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
EW-16	M2XzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnjpTWM2OD1zLkmyO\|Ih\|ryP	MnrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LOXIMVI	NUXLT2hrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFHuSpBKSzVyPUGuPVMzQCEQvF2=	MmHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
GB-1	NYrUN2VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYPJR\|UxRTFwOUO4OlYh\|ryP	M4LrTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
IST-SL2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXLJR\|UxRTJwMECyOlIh\|ryP	NW\Re3NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LAN-6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1[0cWlEPTB;Mj6wNVk3PiEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H510A	NGCzO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUTjVGNFUUN3ME2yMlA1PTB{IN88US=>	M2noOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H1092	NXG0O5BbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWrJR\|UxRTJwMEWxNlQh\|ryP	NE\XOpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HT	NGCwPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlzjTWM2OD1{LkGwOFU1KM7:TR?=	MnvWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
RL95-2	M4HnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYnJR\|UxRTJwMUG0PFIh\|ryP	NIP0ZZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1355	NXjieoUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVKy[VZ6UUN3ME2yMlEyPzl{IN88US=>	MnjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H720	NUXrXHFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NILGb2lKSzVyPUKuNVY5PzNizszN	NH;3Opk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1522	NUnObVZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWrYV3czUUN3ME2yMlIyPzJ\|IN88US=>	M13zclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LB373-MEL-D	MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1TiNGlEPTB;Mj6yOlkxOiEQvF2=	MlLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
DG-75	NEfYboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{L2WWlEPTB;Mj6yO\|E1QCEQvF2=	NG\FV2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ML-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{XLPGlEPTB;Mj6zNlg2PSEQvF2=	NUn4SJQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SF126	M1v6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIr3WJdKSzVyPUKuN\|MxQTRizszN	NE\SUGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
MPP-89	Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml:2TWM2OD1{LkOzNVQ2KM7:TR?=	NWPHcGN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H345	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVSxcZdIUUN3ME2yMlM{Ojd5IN88US=>	NFr6Z4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LS-123	NUnGNWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHPndnpKSzVyPUKuN\|Q6OzZizszN	NGCzPYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NB10	NU\RS2tOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NG\ENYpKSzVyPUKuOFExQTJizszN	Mo\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
CGTH-W-1	M2[0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mlm5TWM2OD1{LkSyNlY4KM7:TR?=	M320T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
CP66-MEL	NVLJfnhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWTUSWc3UUN3ME2yMlQ4PzdizszN	NYOxd5NlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
L-428	MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXnldYw1UUN3ME2yMlQ5PTJzIN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
DMS-79	M1Xh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3P5TGlEPTB;Mj61OFExOyEQvF2=	M{fnVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H1882	MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUnXbYJSUUN3ME2yMlY4PTZ{IN88US=>	M4\DZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KGN	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NELiO5RKSzVyPUKuO\|Y5PzZizszN	M17ZflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
EW-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVjJR\|UxRTJwN{ewPFMh\|ryP	M33o[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
U-266	NELTO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHzOOmpKSzVyPUKuPFQ5OjNizszN	MnzEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
COLO-320-HSR	MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mnq0TWM2OD1{Lki1OlQyKM7:TR?=	M1[3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KMOE-2	NYHNfXBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVzHVlhxUUN3ME2yMlg4PzFzIN88US=>	M1jSS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
BB49-HNC	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoPNTWM2OD1{LkmyOFgh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
GI-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4DoZWlEPTB;Mj65Nlk2PyEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1304	M{mxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFGwNGhKSzVyPUOuNFA2OTFizszN	M1vaeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H2227	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUnnRpVwUUN3ME2zMlAzODd7IN88US=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
U-87-MG	NFvqW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4Pjc2lEPTB;Mz6wN\|UyOyEQvF2=	NELSfIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H747	NGLSdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2jVU2lEPTB;Mz6wOVIxPiEQvF2=	NX\pOYRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
CTB-1	NXy5VWpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml;OTWM2OD1\|LkC1N\|c3KM7:TR?=	NEPMPI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
RPMI-8226	NWPVdGtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3zBN2lEPTB;Mz6xOFM4QCEQvF2=	M4nqZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H2141	NEToeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mly0TWM2OD1\|LkG2OVY3KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
IST-MES1	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1;KT2lEPTB;Mz6xPFI4QSEQvF2=	NIXCNmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
TE-5	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEDHXWlKSzVyPUOuNlE{PDJizszN	NH3rN2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
UACC-257	M3XVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkLITWM2OD1\|LkSzOlU6KM7:TR?=	Ml\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SK-N-FI	M{\qXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXfJR\|UxRTNwNEWyNlch\|ryP	M4\qS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MFH-ino	M2fhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV3JR\|UxRTNwNE[1PFkh\|ryP	M2H4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
SF268	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYTQZZJbUUN3ME2zMlQ5OTd2IN88US=>	NECwVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
TE-12	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXTCTYVJUUN3ME2zMlUyPjl7IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NB6	M1n1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoDLTWM2OD1\|LkW1OVY{KM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
DJM-1	MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4TrVmlEPTB;Mz61PVg6QSEQvF2=	NFm3Vpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
MZ1-PC	MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWXj[pY2UUN3ME2zMlYyPjJ2IN88US=>	NIjYOXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
OCI-AML2	NWjhZlB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlvlTWM2OD1\|Lk[yOlcyKM7:TR?=	NWnPR5N7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H1155	M2nhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFjF[G5KSzVyPUOuO\|A6PDdizszN	NEno[pM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
RKO	NHflWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MY\JR\|UxRTNwN{exPFkh\|ryP	M2TpfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
ECC4	M1nvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoXmTWM2OD1\|Lkm3NVk2KM7:TR?=	NUja[lBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
BB65-RCC	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{\4UWlEPTB;Mz65O\|U1PyEQvF2=	NVr5[5ZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
EB-3	NEDGWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NX6zW3RUUUN3ME2zMlk6PjN\|IN88US=>	NESw[ow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SHP-77	M1uyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYLJR\|UxRTRwMEC1NlQh\|ryP	MmL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H2196	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnWyTWM2OD12LkC1OlI2KM7:TR?=	MoP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
GI-ME-N	NV\pU5lOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXfJR\|UxRTRwME[zPVkh\|ryP	MlT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MN-60	NHSwSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV72b5BFUUN3ME20MlExQDdizszN	NGTZV3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1694	NV3lN\|hXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmHZTWM2OD12LkGzOFA2KM7:TR?=	M{TIbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LU-65	NVL4OXJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4DuOGlEPTB;ND6xOVM{OiEQvF2=	NGHxbI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1436	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4D2UWlEPTB;ND6xPFM{OyEQvF2=	Mn7KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
KINGS-1	NWTWd4ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFLlR49KSzVyPUSuN\|E1OzJizszN	NHLVepY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
GT3TKB	NWfMRXYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUjJR\|UxRTRwM{OyOlgh\|ryP	MlvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
Becker	NVLGOHRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWrGR4pIUUN3ME20MlM4OzF{IN88US=>	NGXFO2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HCC1187	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkLITWM2OD12Lki5OlU4KM7:TR?=	NYDqXXVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
D-502MG	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXvJR\|UxRTVwMEC0NVYh\|ryP	MnezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
VA-ES-BJ	NX\B[5Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NITKSGhKSzVyPUWuNVM4PzhizszN	NYHkbXBVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB7	NHrabphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUn3ZmVNUUN3ME21MlE1OTF{IN88US=>	NIK5T2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SW962	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIDtNGhKSzVyPUWuN\|g5OTRizszN	NFv2bYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
no-11	M1rhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4Dn[GlEPTB;NT63OlM1OyEQvF2=	NVTJWoh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
KNS-81-FD	NITQdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2L6VGlEPTB;NT65NFY6PCEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
COLO-684	M3H6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkPyTWM2OD13Lkm5OFk1KM7:TR?=	NGr4Uos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
D-263MG	MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmfaTWM2OD14LkC4PFk2KM7:TR?=	M371PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
EW-24	NUHBUop7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1XlNWlEPTB;Nj6yPFUyKM7:TR?=	MofZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
TE-10	NGXW[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1fUTmlEPTB;Nj60NlYzOyEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EKVX	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkD4TWM2OD14LkS2N\|IyKM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1648	NYq4ZZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVHBZoJ2UUN3ME22MlY4PTV5IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LB771-HNC	M3TQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF;xZmpKSzVyPU[uPVI{ODFizszN	M2\V[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVzJR\|UxRThwMUOxOlYh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
COLO-668	NIW2RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXe4VI5TUUN3ME24MlI4Pzh4IN88US=>	M3j3V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
EW-12	M3T6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHXkPYhKSzVyPUiuOFA5ODNizszN	NH\2fmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
A253	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2f5cWlEPTB;OD64OFY3OSEQvF2=	MmiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H2126	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1PS[GlEPTB;OD64PVMyQSEQvF2=	NVPMZWJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
Calu-6	MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEHmPYNKSzVyPUiuPVkxPDJizszN	NFHLbWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H23	NXvJcWNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXnJR\|UxRTlwMUe3OFYh\|ryP	NEfpUmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
WSU-NHL	NF32WW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXXJR\|UxRTlwN{e0O\|gh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MMAC-SF	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFfPVXJKSzVyPUmuPVc6ODRizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SK-LMS-1	NVHpU5JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIroVpJKSzVyPUGwMlI5OzRizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
GCIY	M3jDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4S4[WlEPTB;MUCuOVkzPCEQvF2=	M1TjNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
TE-15	NV\CXHRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIn6bnVKSzVyPUGxMlYxODRizszN	MmnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
EoL-1-cell	M17qbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFLVXFhKSzVyPUGxMlc3QDJizszN	NIDsdmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H2081	NI[4TmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3jEOWlEPTB;MUGuO\|c5PiEQvF2=	M3TOeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
EW-3	M{PKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWnJR\|UxRTF{LkK0OlMh\|ryP	NHTHWYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
CAS-1	NF\rOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M13iU2lEPTB;MUKuN\|Y{OSEQvF2=	MmWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
C2BBe1	M2DSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFr3Z\|FKSzVyPUGyMlYyOzFizszN	NHXPZnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
D-247MG	NEHzbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXnV[nR[UUN3ME2xNk44QTV{IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-SNU-5	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYHVZ495UUN3ME2xNk45ODF\|IN88US=>	M2DrUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LS-1034	M1\afWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUOxd4xKUUN3ME2xOE4{QTd3IN88US=>	M1j3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
EW-18	M3WwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlmxTWM2OD1zND60OFgh\|ryP	NUTaN2NDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
Raji	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2fB[GlEPTB;MUSuOVA1QSEQvF2=	NWTme5RMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
D-283MED	NYnIeXI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4HLWGlEPTB;MUSuOlI4OSEQvF2=	NVKyN5FCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MZ2-MEL	M4WxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVz1RoYyUUN3ME2xOE46Pjl4IN88US=>	M{fjSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-SNU-16	MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGrwb3pKSzVyPUG1MlQ3OzNizszN	MmTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
P30-OHK	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{P0RmlEPTB;MUeuO\|g{OSEQvF2=	NY\6bFI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
RXF393	Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{X2NGlEPTB;MUmuNFE5PiEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1395	NIe1WWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYnLO\|QyUUN3ME2yNE43PzB\|IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
U-698-M	M3fCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUT1enZoUUN3ME2yNE44ODd3IN88US=>	NXW4UXRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-SNU-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVLBWGNbUUN3ME2yNE44OjJ\|IN88US=>	NFPBdGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SW684	NIrDbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmDTTWM2OD1{MT6xO\|E3KM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H716	M1S0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVfJR\|UxRTJzLkOxOVQh\|ryP	NXz4WGdLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
JVM-2	M{jPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXjJR\|UxRTJzLkSxN\|Mh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1581	M1Tvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFnqU29KSzVyPUKyMlQyPDhizszN	NXW2b3hzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
CA46	NH7OUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkfpTWM2OD1\|MT62PVM3KM7:TR?=	M1LGZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
SNB75	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYjGUld5UUN3ME2zN{43PTB\|IN88US=>	M3z6NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KNS-42	NX\HRnZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV3JR\|UxRTN3Lkm2NlQh\|ryP	NYPYW2RDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
TUR	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2DGbmlEPTB;M{[uNFUzOSEQvF2=	NVq2WVlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
REH	MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVzJR\|UxRTN5LkiyNVEh\|ryP	NWrTUGlIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
EW-22	M3;Jd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXTw[VE5UUN3ME20Nk4zQDh3IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H446	NUm2N5RET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3vJZWlEPTB;NEKuO\|g2OyEQvF2=	NVvGU\|FjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ES3	MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH7HW5NKSzVyPUSzMlE{OzlizszN	NELDSGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
EW-11	NXf3T2tpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVTrdJg4UUN3ME20OE45OjF6IN88US=>	NXSxb2lpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
RH-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHj0S2xKSzVyPUS3MlU5OTJizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HepG2	M362O2Z2dmO2aX;uJIF{e2G7			M{Hhb2lvcGmkaYTpc44hd2ZiaIXtZY4hUGWyR{KgZ4VtdHNuIFnDOVAhRSByLkCwNFkh\|ryPLh?=	NI\QeJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
HCT116	MmT5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NULoVYF1PDhiaILz	M2HMPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEh\|ryPLh?=	MnP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MEWwNlIoRjJ{N{C1NFIzRC:jPh?=
A549	M{S0OWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1HxTFQ5KGi{cx?=	NEHTbJBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNUDPxE1w	NWPnZVc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NFUxOjJpPkKyO\|A2ODJ{PD;hQi=>
HEK293	MWHGeY5kfGmxbjDhd5NigQ>?			MVrJcohq[mm2aX;uJI9nKGi3bXHuJGMufGW{bXnuZYwhTkyDRz30ZYdo\WRiSFTBR\|EhcW5iSFXLNlk{KGOnbHzzMEBKSzVyIE2gNE4yOiEQvF2u	M2OxbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NESxPFQ3Lz5zOUS0NVg1PjxxYU6=
HEK293	MXLGeY5kfGmxbjDhd5NigQ>?			NU\3cYM3UW6qaXLpeIlwdiCxZjDISGFEOSCrbjDISWszQTNiY3XscJMtKEmFNUCgQUAxNjF{IN88UU4>	NX73b5RKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNFg2PjNpPkG4N\|A5PTZ\|PD;hQi=>
SNU16	NI\EeGNHfW6ldHnvckBie3OjeR?=			MoS3TY5pcWKrdHnvckBw\iCKRFHDJIZzd21iaIXtZY4hW06XMU[gZ4VtdHNuIFnDOVAhRSByLkKzN{DPxE1w	NYnlOGUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
HEK293	MXfGeY5kfGmxbjDhd5NigQ>?			NFvjbXRKdmirYnn0bY9vKG:oIHj1cYFvKENvdHXycYlv[WxiRlzBS{11[WepZXSgTGRCSzJiaX6gTGVMOjl\|IHPlcIx{NCCLQ{WwJF0hOC5{NTFOwG0v	M4TZRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NESxPFQ3Lz5zOUS0NVg1PjxxYU6=
U937	NE\pUopHfW6ldHnvckBie3OjeR?=			NYHES5JKUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNUBqdiCXOUO3JINmdGy\|IHL5JIludXWwb4Dy[YNqeGm2YYTpc44h[XO\|YYmsJGlEPTBiPTCwMlMh\|ryPLh?=	NVzuSm1XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPFEzOzhpPkG4N\|gyOjN6PD;hQi=>
SK-N-BE(2)	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWO0PEBpenN?	M{PFb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1DTSh{KTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5\|MzFOwG0v	M3[4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUGxPVA3Lz5{OEWxNVkxPjxxYU6=
AGS	NGHSOWtCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3rpWlczKGi{cx?=	NGnrcFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFHHV{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6zOEDPxE1w	NYfqT\|F4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3PFczPjJpPkK5O\|g4OjZ{PD;hQi=>
MCF7	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MoXWOFghcHK\|	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNidILlZZRm\CCob4KgOFghcHK\|IH\vcIxwf2WmIHL5JJJm\nKnc3jl[EBmfmW{eTC5OkBpenNibXXhd5Vz\WRib36g[IF6KDFyIHL5JGxwf3K7IHHzd4F6NCCLQ{WwJF0hOC5\|NTFOwG0v	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZzM{[zOUc,OjZ4MUO2N\|U9N2F-
HEK293	MYfGeY5kfGmxbjDhd5NigQ>?			NX7tU4kxUW6qaXLpeIlwdiCxZjDoeY1idiCFLYTldo1qdmGuIF\MRWcufGGpZ3XkJGhFSUN\|IHnuJGhGUzJ7MzDj[YxteyxiSVO1NEA:KDBwNDFOwG0v	NFzXeJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS0NVg1Pid-MUm0OFE5PDZ:L3G+
HEK293	MnXsSpVv[3Srb36gZZN{[Xl?			NF7aWFJKdmirYnn0bY9vKG:oIFjERWM{KGmwIFjFT\|I6OyClZXzsd{whUUN3MDC9JFAvPCEQvF2u	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNyOEW2N{c,OTh\|MEi1OlM9N2F-
HEL	MlLBSpVv[3Srb36gZZN{[Xl?		MnrEN{BpenN?	MkL4TY5pcWKrdHnvckBw\iClbHHzd{AyKEiGQVOgbY4hUEWOIHPlcIx{KHW\|aX7nJGJw[y2OeYOgLIFk\XS7bDmtRW1EKGG\|IIP1ZpN1emG2ZTDwdoVqdmO3YnH0[YQh\m:{IEOgbJJ{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkSzJO69VS5?	NG\WSpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWxNVkxPid-Mki1NVE6ODZ:L3G+
PC3	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3rpRlQ5KGi{cx?=	NX\JN3Q{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN\|IHPlcIx{KGGodHXyJFQ5KGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDHTVUxKD1iMD60N{DPxE1w	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN7NUG1NEc,Ojh\|OUWxOVA9N2F-
HEL	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnTWO\|IhcHK\|	NWrvVFloSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDISWwh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuOFQh\|ryPLh?=	Ml7CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5OEeyOlIoRjJ7N{i3NlYzRC:jPh?=
MOLT4	Mm\6RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3TTV\|czKGi{cx?=	M1zO[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MWFQh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuOFUh\|ryPLh?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd6N{K2Nkc,Ojl5OEeyOlI9N2F-
HCT116	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NH3YU2k4OiCqcoO=	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLMVgh[XO\|YYmsJGlEPTBiPTCwMlQ4KM7:TT6=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkO5O{c,Ojl{MEKzPVc9N2F-
HEL	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3LOPVQ5KGi{cx?=	MnTRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDISWwh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuOFgh\|ryPLh?=	NITrPHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWxNVkxPid-Mki1NVE6ODZ:L3G+
HCT116	M1zyXWZ2dmO2aX;uJIF{e2G7			M{X2UWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy\|LDDJR\|UxKD1iMD61JO69VS5?	MoP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
U937	MnviRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NUnxb4Q2PzJiaILz	NID4S3BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW5N\|ch[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD61OUDPxE1w	M2TPVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUWzO\|IzLz5{NUm1N\|czOjxxYU6=
U937	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NXjWUJpNPzJiaILz	M3zKNGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIFnfGW{IEeyJIhzeyCkeTDNWHQu[mG\|ZXSgZZN{[XluIFnDOVAhRSByLkW1JO69VS5?	M{jWdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe0N\|I3Lz5{NUi3OFMzPjxxYU6=
HCT116	M1qxU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUGyJIRigXN?	NXrlTox5T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy\|IHHmeIVzKDJiZHH5d{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLk[g{txONg>?	NVyw[ZRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFE{QTRpPkKyOVQyOzl2PD;hQi=>
HL60	M12wRmZ2dmO2aX;uJIF{e2G7		MkjzN{BpenN?	NXTDOGdnUW6qaXLpeIlwdiCxZjDjcIF{eyBzIFjERWMhcW5iaIXtZY4hUEx4MDDj[YxteyC3c3nu[{BDd2NvQXOtUJl{NUGPQzDhd{B{fWK\|dILheIUhcW6ldXLheIVlKG[xcjCzJIhzeyCob3zsc5dm\CCkeTDzeYJ{fHKjdHWgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMD62NkDPxE1w	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzNUCwPUc,Ojh2MUWwNFk9N2F-
MOLT4	MYnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVq0PEBpenN?	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTGS0JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLk[1JO69VS5?	NI\BOZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWxNVkxPid-Mki1NVE6ODZ:L3G+
HCT116	NGfsUnNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NGDqSGNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{whUUN3MDC9JFAvPjdizszNMi=>	Mn;jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5NEK0PVYoRjJzN{SyOFk3RC:jPh?=
HCT116	NFvU[WJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NULLOplTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25uIFnDOVAhRSByLk[3JO69VS5?	NXzkdHVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2OVAzOjFpPkKxOlUxOjJzPD;hQi=>
HCT116	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWq3NkBpenN?	NFvhbVVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGC1N{BmgHC{ZYPzbY5oKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscJRqfGW{LXLseYUh[2WubDD2bYFjcWyrdImgZZN{[XluIFPDOVAhRSByLkeg{txONg>?	NYmyNY85RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OFE5PDZpPkG5OFQyQDR4PD;hQi=>
HCT116	MX3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			MkDNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZpkhS2WubGTpeIVzNUKudXWgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjdizszNMi=>	NXLVbJB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|A{PzNpPkG4N\|cxOzd\|PD;hQi=>
HEK293T	NIHCeoFHfW6ldHnvckBie3OjeR?=		NWfnPIhSOSCqch?=	MX\Jcohq[mm2aX;uJI9nKE[OQVeteIFo\2WmIFjERWMzKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIFjFT\|I6O1RiY3XscJMhfXOrbnegZYNmfHmuYYTl[EBtgXOrbnWgd4ll\SClaHHpckBieyC\|dXLzeJJifGViYX\0[ZIhOSCqcjDifUBkd2yxcnnt[ZRzcWNiZHX0[YN1cW:wIHLhd4VlKGG\|c3H5MEBKSzVyIE2gNE44PCEQvF2u	NYq4fploRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFk5QDVpPkK5Nlg6QDh3PD;hQi=>
ML1	NHHNUGdCdnSrdIXtc5Ih[XO\|YYm=			NX;iOmo4SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdW:3c3WgUWwyKGOnbHzzMEBKSzVyIE2gNE44PSEQvF2u	MnzmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3M{S1N\|QoRjF7NUO0OVM1RC:jPh?=
HCT116	Mo\KRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MlHBN{Bl[Xm\|	MlHoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IGfTWE0yKGG\|c3H5MEBKSzVyIE2gNE44PiEQvF2u	NYHtdYI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNlEzOTVpPkKyN\|IyOjF3PD;hQi=>
U937	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3THXFQ5KGi{cx?=	M1;BUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD63O{DPxE1w	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzNUCwPUc,Ojh2MUWwNFk9N2F-
HCT116	NInWbYhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M{jkZ\|czKGi{cx?=	MmnyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBi\nSncjC3NkBpenNiYomgUXRVNWKjc3XkJIF{e2G7LDDJR\|UxKD1iMD63PEDPxE1w	NYrsOnZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|Q{OjZpPkK1PFc1OzJ4PD;hQi=>
K562	MoTPSpVv[3Srb36gZZN{[Xl?		NE\CU3EyOCCvaX7z	MkDFTY5pcWKrdHnvckBw\iCNRFHDN{BqdiCqdX3hckBMPTZ{IHPlcIx{KHW\|aX7nJHs{UF2jY3X0fYxifGWmIHjpd5RwdmViYYOgd5Vje3S{YYTlJIlv[3WkYYTl[EBnd3JiMUCgcYlveyCkeTDsbZF2cWRic3PpcpRqdGyjdHnvckBkd3WwdHnu[{Bu\XSqb3SsJGlEPTBiPTCwMlc6KM7:TT6=	NWC3d2ZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2PFE1ODRpPkK2OlgyPDB2PD;hQi=>
HCT116	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=		M1m2Z\|Mh\GG7cx?=	MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JHdUXC1zIHHzd4F6NCCLQ{WwJF0hOC56IN88UU4>	MoO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NUKyNlYoRjJyNEWyNlI3RC:jPh?=
SKBR3	NUXCVotKSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NHHGfXFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLRnI{KGOnbHzzMEBKSzVyIE2gNE45PyEQvF2u	NYfObWt{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
Sf9	NIjB[pJHfW6ldHnvckBie3OjeR?=		MYCzJIhzew>?	NHXEcoJKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGMufGW{bXnuZYwhUGm\|LYTh[4dm\CCKRFHDNVEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4Y6KGOnbHzzJJV{cW6pIFHjMWFz\y2JbImtUJl{MEGlKT3BUWMh[XNic4Xid5Rz[XSnIIDy[ZRz\WG2ZXSg[o9zKDNiaILzJIZwdGyxd3XkJIJ6KHO3YoP0doF1\SCjZHTpeIlwdiCjZoTldkA{OCCvaX7zJIJ6KG[udX;yc41mfHKrYzDt[ZRpd2RuIFnDOVAhRSByLkmg{txONg>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVyMUWxOEc,Ojh3MEG1NVQ9N2F-
S2	Ml23SpVv[3Srb36gZZN{[Xl?			MkK4TY5pcWKrdHnvckBw\iCSbHHzcY9lcXWvIH\hcINqeGG{dX2gTGRCSzFiZYjwdoV{e2WmIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy\|LDDJR\|UxKD1iMD65OEDPxE1w	MoHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|MUe0OVAoRjF7M{G3OFUxRC:jPh?=
HEK293T	NWjtN49bTnWwY4Tpc44h[XO\|YYm=		NWPSb\|BzOSCqch?=	MVHJcohq[mm2aX;uJI9nKGi3bXHuJGZNSUdvdHHn[4VlKEiGQVOxJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJJV{cW6pIHHj[ZR6dGG2ZXSgcJl{cW6nIIPp[IUh[2ijaX6gZZMhe3Wkc4TyZZRmKGGodHXyJFEhcHJiYomgZ49td3KrbXX0dolkKGSndHXjeIlwdiCkYYPl[EBie3OjeTygTWM2OCB;IEGuNFch\|ryPLh?=	NUm3fYY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFk5QDVpPkK5Nlg6QDh3PD;hQi=>
A549	M3X1WGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFzHdGg4OiCqcoO=	M13NNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUEWzJIV5eHKnc4PpcochSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2WubITpeIVzNWKudXWgZ4VtdCC4aXHibYxqfHliYYPzZZktKEOFNUCgQUAyNjJizszNMi=>	NH3JeJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS0NVg1Pid-MUm0OFE5PDZ:L3G+
A549	M{DZc2FvfGmycn;sbYZmemG2aY\lJIF{e2G7			MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYomgR4VtdFSrdHXyMWJtfWViY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlIh\|ryPLh?=	M37lTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ewN\|c{Lz5zOEO3NFM4OzxxYU6=
HEK293T	NULLfYl1TnWwY4Tpc44h[XO\|YYm=		M1zh[VEhcHJ?	M1W0OGlvcGmkaYTpc44hd2ZiaIXtZY4hTkyDRz30ZYdo\WRiSFTBR\|Mh\XiycnXzd4VlKGmwIFjFT\|I6O1RiY3XscJMhfXOrbnegZYNmfHmuYYTl[EBtgXOrbnWgd4ll\SClaHHpckBieyC\|dXLzeJJifGViYX\0[ZIhOSCqcjDifUBkd2yxcnnt[ZRzcWNiZHX0[YN1cW:wIHLhd4VlKGG\|c3H5MEBKSzVyIE2gNU4zOyEQvF2u	NIDa[ZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PVg5PSd-MkmyPFk5QDV:L3G+
HEL	Mkn6RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M4eweVQ5KGi{cx?=	NV[0SIhPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBJTUxiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEvOjlizszNMi=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzNUCwPUc,Ojh2MUWwNFk9N2F-
G401	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4\yTVczKGi{cx?=	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEd2MEGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHz0bZRmei2kbIXlJINmdGxidnnhZoltcXS7IHHzd4F6NCCFQ{WwJF0hOS5\|IN88UU4>	M4ToZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NESxPFQ3Lz5zOUS0NVg1PjxxYU6=
G401	NYDyZlNwSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEd2MEGgZ4VtdHNiYomgR4VtdFSrdHXyMWJtfWViY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlMh\|ryPLh?=	Mn:5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|N{CzO\|MoRjF6M{ewN\|c{RC:jPh?=
Sf9	M{fYcWZ2dmO2aX;uJIF{e2G7		MYmzJIhzew>?	MnWwTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDMZRmem2rbnHsJGhqey22YXfn[YQhUESDQ{GxJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmPUBk\WyuczD1d4lv\yCDYz3BdocuT2y7LVz5d{hC[ylvQV3DJIF{KHO3YoP0doF1\SCycnX0doVifGWmIH\vdkA{KGi{czDmc4xtd3enZDDifUB{fWK\|dILheIUh[WSmaYTpc44h[W[2ZYKgN\|AhdWmwczDpckBxemW\|ZX7j[UBw\iByLkKgeW0hW0GKQTDifUBnNCCLQ{WwJF0hOS5\|IN88UU4>	NVHDeWh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NFE2OTRpPkK4OVAyPTF2PD;hQi=>
K562	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NI\rXGc1QCCqcoO=	NI[wTmtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuN\|Ih\|ryPLh?=	NFXKTmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWxNVkxPid-Mki1NVE6ODZ:L3G+
Huh7	MWDBcpRqfmm{YXygZZN{[Xl?		MXuzJIRigXN?	M1nBW2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhEXiCpZX7veJlx\SBzYjDpcoZm[3SnZDDpckBpfW2jbjDIeYg4KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUCgQUAyNjRizszNMi=>	NVHjN2tqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PVA4ODBpPkK1OFkxPzByPD;hQi=>
MDA-MB-231	NV7Ob\|k3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUTMeI9SPDhiaILz	NU\OfWJ3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDFwNEGg{txONg>?	NGrVSGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO5OVE2OCd-MkizPVUyPTB:L3G+
K562	NX\RN4hKTnWwY4Tpc44h[XO\|YYm=		NHr6VHkyOCCvaX7z	M{T0dWlvcGmkaYTpc44hd2ZiS1TBR\|EhcW5iaIXtZY4hUzV4MjDj[YxteyC3c3nu[{BcO0ifYXPleJlt[XSnZDDobZN1d26nIHHzJJN2[nO2cnH0[UBqdmO3YnH0[YQh\m:{IEGwJI1qdnNiYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcochdWW2aH;kMEBKSzVyIE2gNU41QCEQvF2u	M2DoZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkixOFA1Lz5{Nk[4NVQxPDxxYU6=
HL60	NXjPdoRSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVi0UnlUPDhiaILz	NUfwUZZVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlUzKM7:TT6=	M4rKWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEG1NFA6Lz5{OESxOVAxQTxxYU6=
HeLa	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NX;xUZRCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBJ\UyjIHPlcIx{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMT61PFQ5QSEQvF2u	Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4ME[zO\|AoRjF5NkC2N\|cxRC:jPh?=
HeLa	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NH3WcZE4OiCqcoO=	NWHp[HVOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFEvPiEQvF2u	Mo\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEKzPVcoRjJ7MkCyN\|k4RC:jPh?=
K562	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWm0PEBpenN?	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNkig{txONg>?	Mlr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MUWwNFkoRjJ6NEG1NFA6RC:jPh?=
HeLa	NVTpXZFFSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWTSZ25jPzJiaILz	M2nXVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUEWzMYRm\mmlaXXueEBJ\UyjIHPlcIx{KGGodHXyJFczKGi{czDifUBk\WyudHn0[ZIu[my3ZTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhS0N3MDC9JFEvQCEQvF2u	NYfUUlJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OFE5PDZpPkG5OFQyQDR4PD;hQi=>
HeLa	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			M2TYfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDifUBE\WyuVHn0[ZIuSmy3ZTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvQCEQvF2u	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN5MEO3N{c,OTh\|N{CzO\|M9N2F-
HCT116	M1Wzb2Z2dmO2aX;uJIF{e2G7		NGPiOosyQCCqcoO=	NF;WRoZKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hUEOWMUG2JINmdGy\|IIXzbY5oKEKxYz3MfZMhMGWyc3nsc44uSWNrLVHNR{BieyC\|dXLzeJJifGVicILleJJm[XSnZDDmc5IhOThiaILzJIZwdGyxd3XkJIJ6KHO3YoP0doF1\SCjZHTpeIlwdiCjZoTldkA{KGi{czDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAyNjl4IN88UU4>	NFviPFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO0NFQyOyd-MkizOFA1OTN:L3G+
DU145	NXjlTWdWS3m2b4TvfIlkcXS7IHHzd4F6			NVfoTppHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNkDPxE1w	MoXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzM{GyOFgoRjF7MUOxNlQ5RC:jPh?=
K562	MV7GeY5kfGmxbjDhd5NigQ>?			MXTJcohq[mm2aX;uJI9nKGi3bXHuJIhqe3SxbnWg[IVi[2W2eXzhd4UhMG2reIT1doUhd2ZiSFTBR\|Eh[W6mIFjERWMzMSCycnXwZZJm\CCocn;tJGs2PjJiZYL5eIhzd2yndXvlcYliKGOnbHzzMkwhUUN3MDC9JFIh\|ryPLh?=	NXyzXFNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK0NVk{QDBpPkGyOFE6OzhyPD;hQi=>
K562	M{LadmZ2dmO2aX;uJIF{e2G7			NHmyT\|ZKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhUGm\|dH;u[UBl\WGlZYT5cIF{\SBqSFTBR{khcW5iSzC1OlIh\XK7dHjyc4xmfWunbXnhJINmdGy\|LDDJR\|UxKD1iMjFOwG0v	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7MkS3N{c,OTR3OUK0O\|M9N2F-
HCT116	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWC0PEBpenN?	NVnIRmM6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIvODNizszNMi=>	M4TZd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{SwOFE{Lz5{OEO0NFQyOzxxYU6=
HCT116	NXnC[Xp3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2HpSlQ5KGi{cx?=	NV7leGNQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIvODdizszNMi=>	MlPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MUWwNFkoRjJ6NEG1NFA6RC:jPh?=
NCI-H661	NUnMdmVsSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUPzPXU5PzJiaILz	NGjFRZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPjZzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDndo94fGhiYX\0[ZIhPzJiaILzJIJ6KE2WVD3iZZNm\CCjc4PhfUwhUUN3MDC9JFIvOTlizszNMi=>	NYKwOmllRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|Q{OjZpPkK1PFc1OzJ4PD;hQi=>
NCI-H661	NWr2fIhJSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MlvRO\|IhcHK\|	M{P2fmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg3PjFiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNk4yQSEQvF2u	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl3M{eyNkc,OjV7NUO3NlI9N2F-
SNU-16	M4\M[WZ2dmO2aX;uJIF{e2G7			NIe0VWxKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhUGm\|dH;u[UBl\WGlZYT5cIF{\SBqSFTBR{kh\nKxbTDTUnUuOTZiKHj1cYFvKGejc4TybYMh[WSnbn;jZZJkcW6xbXGpJINmdGy\|LDDJR\|UxKD1iMj6xPVQ2QSEQvF2u	NV\NZm5qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS2OlczOjdpPkG0OlY4OjJ5PD;hQi=>
Sf9	MYPGeY5kfGmxbjDhd5NigQ>?		NH\VeVUyPyCqcoO=	MWrJcohq[mm2aX;uJI9nKEirc{[teIFo\2WmIFjERWM{N1OPUmSgLFM6PSC2bzC0PFkhemW\|aXT1[ZMqKCi3bnvuc5dvKG:{aXfpckkh[29vZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoOTDj[YxteyC3c3nu[{ApTkGPKT3sZYJmdGWmIHHj[ZR6dGG2ZXSgdIVxfGmmZTDzeYJ{fHKjdHWgZYZ1\XJiMUegbJJ{KGK7IHPhcIlx\XJibXnjdo9ndHWrZHnjJI1w[mmuaYT5JJNpcW[2IHHzd4F6NCCLQ{WwJF0hOi5\|MUKwOkDPxE1w	M4fk[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUe5O\|Q6Lz5\|MEG3PVc1QTxxYU6=
ACHN	MmGzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVnLOJBSPzJiaILz	M2\tZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQVPIUkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj60JO69VS5?	NHrrfYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe4O\|I3Oid-Mkm3PFczPjJ:L3G+
SGC7901	M2C0VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1\odVczKGi{cx?=	NUnTXXNNT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0eFN{mwNUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCZU2Sg[JlmKHKnZIXjeIlwdiCjc4PhfUwhT0l7MDC9JFIvPSEQvF2u	NVi5fIhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlE{PzZpPkKzNFYyOzd4PD;hQi=>
MDA-MB-231	M3zhUWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1HaOFczKGi{cx?=	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIvPTVizszNMi=>	NUT1O2J5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3PFczPjJpPkK5O\|g4OjZ{PD;hQi=>
MDA-MB-231	MYjBcpRq[2GwY3XyJIF{e2G7		M1fBUFczKGi{cx?=	M3H2OGFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJJF0hOi56IN88UU4>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd2MUizOEc,OjF5NEG4N\|Q9N2F-
A2780	M3flNmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NUTKdVlUPzJiaILz	Mm[2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDMke4NEBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscJRqfGW{LXLseYUh[2WubDD2bYFjcWyrdImgZZN{[XluIFPDOVAhRSB\|IN88UU4>	M{DrO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NESxPFQ3Lz5zOUS0NVg1PjxxYU6=
A2780	NWL4RoRsSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M2XifWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUK3PFAh[2WubIOgZpkhS2WubGTpeIVzNUKudXWgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{KM7:TT6=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN5MEO3N{c,OTh\|N{CzO\|M9N2F-
HCT116	MWDBcpRq[2GwY3XyJIF{e2G7		MlHQO\|IhcHK\|	M1\jNmFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhT0liPTCzMlEh\|ryPLh?=	M1H3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{SxPFM1Lz5{MUe0NVg{PDxxYU6=
HT-29	M3LaeGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MnXaO\|IhcHK\|	Ml\hRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMz6xJO69VS5?	M1;kVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{i3NlYzLz5{OUe4O\|I3OjxxYU6=
A549	M3W5[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVy0PEBpenN?	M1fPVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMz6xNUDPxE1w	NHiwOm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO0NFQyOyd-MkizOFA1OTN:L3G+
A549	NUPQVmRKS3m2b4TvfIlkcXS7IHHzd4F6		MVm3NkBpenN?	MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCzMlE{PCEQvF2u	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF2MEm2NUc,OjZzNEC5OlE9N2F-
A2780	NFzPT2pHfW6ldHnvckBie3OjeR?=		MXWxPEBpenN?	MVHJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gRVI4QDBiY3XscJMhfXOrbnegRo9kNUy7czCo[ZB{cWyxbj3BZ{kuSU2FIHHzJJN2[nO2cnH0[UBxemW2cnXheIVlKG[xcjCxPEBpenNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IEOuNVUh\|ryPLh?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN2MESxN{c,Ojh\|NEC0NVM9N2F-
SW620	NYXJfI1RTnWwY4Tpc44h[XO\|YYm=			NYHsSWlMUW6qaXLpeIlwdiCxZjDoeY1idiCVV{[yNEBk\WyuczygTWM2OCB;IEOuNkDPxE1w	M4frcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkS3OVU1Lz5zOEK0O\|U2PDxxYU6=
HeLa	MXzGeY5kfGmxbjDhd5NigQ>?		M2TYT\|MxKG2rboO=	MVrJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNiaX6gTIVN[SClZXzsd{Bi\nSncjCzNEBucW6\|IHL5JGZtfW:{IHTlJGx6eyCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSB\|LkKg{txONg>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh6OUO0N{c,OjF6OEmzOFM9N2F-
A549	MUHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NYeyNZhVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzMEBKSzVyIE2gN{42QCEQvF2u	NVT0XlRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
K562	NUPHPWZtSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mk\6O\|IhcHK\|	MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDNwNk[g{txONg>?	MlTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5OEeyOlIoRjJ7N{i3NlYzRC:jPh?=
A375	NVHIOnNmSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWf0SJZRPzJiaILz	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF\|N{WgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFSz24JIF{e2G7LDDJR\|UxKD1iMz62O{DPxE1w	NE\aXJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlM6Pyd-MkmyNFI{QTd:L3G+
MCF7	Mn\IRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVK0PEBpenN?	M1PvUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iND6wNkDPxE1w	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN2MESxN{c,Ojh\|NEC0NVM9N2F-
MKN45	NY[yTFFCSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NHvTN2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzMEBKSzVyIE2gOE4yPiEQvF2u	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
MCF7	MVXGeY5kfGmxbjDhd5NigQ>?			NXPqcopLUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGy\|LDDJR\|UxKD1iND6zJO69VS5?	NID3eok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
HL60	Ml3rRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGXuN\|Q1QCCqcoO=	NFnzS5RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IESuOVMh\|ryPLh?=	NGHISIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO0NFQyOyd-MkizOFA1OTN:L3G+
MDA-MB-231	NVrhbVJiSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnywO\|IhcHK\|	Ml\YRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDndo94fGhiYX\0[ZIhPzJiaILzJIJ6KE2WVD3iZZNm\CCjc4PhfUwhUUN3MDC9JFQvPjNizszNMi=>	MmDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{SzNlYoRjJ3OEe0N\|I3RC:jPh?=
K562	MmW3SpVv[3Srb36gZZN{[Xl?			Mki0TY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JJBienSrYXzsfUBxfXKrZnnl[EBpcXO2b37lJIRm[WOndInsZZNmKG:oIHj1cYFvKGyndXvlcYliKEt3NkKgZ4VtdHNwLDDJR\|UxKD1iND64JO69VS5?	NUD2d4FKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC0NlUyOTBpPkGwOFI2OTFyPD;hQi=>
HeLa	NGrBN29HfW6ldHnvckBie3OjeR?=			MnjLTY5pcWKrdHnvckBw\iCKRFHDJIZzd21iaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDv[kBpcXO2b37lJGg{KGGlZYT5cIF1cW:wLDDJR\|UxKD1iND64JO69VS5?	NVL4[3VERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N\|Q2OzRpPkG5OVM1PTN2PD;hQi=>
MGC803	M3PEe2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYjH[3o{PzJiaILz	NX\yN2s4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNS2M5ODNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNEUy16IHHzd4F6NCCLQ{WwJF0hPC56OTFOwG0v	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkO5O{c,Ojl{MEKzPVc9N2F-
PC3	MkTLRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHjGe3Y1QCCqcoO=	NWDiUHM1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IESuPFkh\|ryPLh?=	M3npTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUGxPVA3Lz5{OEWxNVkxPjxxYU6=
HuH7	MVzDfZRwfG:6aXPpeJkh[XO\|YYm=		MUizJIRigXN?	M2exUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh2UDdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB\|IHThfZMh[nliQ3XscHRqfGW{IEm2JIF{e2G7LDDDR\|UxKD1iNT6xJO69VS5?	NYPmUWJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PVA4ODBpPkK1OFkxPzByPD;hQi=>
HCT116	MkDwR5l1d3SxeHnjbZR6KGG\|c3H5		MXW3NkBpenN?	Mnf1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA2NjFizszNMi=>	M1fuV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUSwPVYyLz5{NkG0NFk3OTxxYU6=
A549	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWq3NkBpenN?	Mn61RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZYZ1\XJiN{KgbJJ{KGK7IF3UWE1j[XOnZDDhd5NigSxiSVO1NEA:KDVwNEGg{txONg>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5NEOyOkc,OjV6N{SzNlY9N2F-
A549	M4\xdWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MUK3NkBpenN?	NWDjNVlNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWuOFEh\|ryPLh?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl3M{eyNkc,OjV7NUO3NlI9N2F-
A2780	NGDmZZVCdnSrY3HuZ4VzKGG\|c3H5		M3\LXVczKGi{cx?=	M{XxZWFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBIUSB;IEWuO{DPxE1w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd2MUizOEc,OjF5NEG4N\|Q9N2F-
A549	NXGxNIFiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{\ucVQ5KGi{cx?=	MXzHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwJF0hPS55NjFOwG0v	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN7NUG1NEc,Ojh\|OUWxOVA9N2F-
A2780	NIC2Z4pCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M13BTFQ5KGi{cx?=	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF{N{iwJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB3Lki5JO69VS5?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN2MESxN{c,Ojh\|NEC0NVM9N2F-
SMMC7721	NVS4cmw6SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MonzO\|IhcHK\|	NGK2VJBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPNUWM4PzJzIHPlcIx{KGGodHXyJFczKGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDVwOUeg{txONg>?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkO5O{c,Ojl{MEKzPVc9N2F-
U266	NVHCeWR3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MlPkOFghcHK\|	M1;4cWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUK2OkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNj6xJO69VS5?	M1P5[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEG1NFA6Lz5{OESxOVAxQTxxYU6=
PC3	M{\SV2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1zMTFQ5KGi{cx?=	NHLTbGhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNj6zOkDPxE1w	NGXGV2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO0NFQyOyd-MkizOFA1OTN:L3G+
U251	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NH7NS\|YzKGSjeYO=	MU\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDVNlUyKGOnbHzzJIFnfGW{IEKg[IF6eyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTC2MlUh\|ryPLh?=	M2G5V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSxN\|k1Lz5{MkW0NVM6PDxxYU6=
NCI-H1299	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1nLelczKGi{cx?=	NH;LdmJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTJ7OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONLUigZZN{[XluIFnDOVAhRSB4Lke0JO69VS5?	NUXxRo1ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNFI{QTdpPkK5NlAzOzl5PD;hQi=>
AsPC1	M4HW[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MljtOFghcHK\|	NXLDOFZ1T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSXOSQ{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmsJGdKPTBiPTC2Mlkh\|ryPLh?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN7NUG1NEc,Ojh\|OUWxOVA9N2F-
BGC823	M4Xldmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1HielczKGi{cx?=	MYXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDCS2M5OjNiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVKGS7ZTDy[YR2[3Srb36gZZN{[XluIFfJPVAhRSB5LkGg{txONg>?	Moq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkGzO\|YoRjJ\|ME[xN\|c3RC:jPh?=
MCF7	NFLsZlJEgXSxdH;4bYNqfHliYYPzZZk>		NUPte5Y4PzJiaILz	NX;lO3lwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPy56OEGg{txONg>?	MoHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNEC5OlEoRjJ4MUSwPVYyRC:jPh?=
DU145	MWrBcpRq[2GwY3XyJIF{e2G7		NVnmSGkzPzJiaILz	M{PFSWFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBIUSB;IEeuPUDPxE1w	NIHQTFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe0NVg{PCd-MkG3OFE5OzR:L3G+
Bel7402	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXm3NkBpenN?	NE\LOmdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBD\Wx5NECyJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KFeVVDDkfYUhemWmdXP0bY9vKGG\|c3H5MEBIUTlyIE2gPEDPxE1w	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MUO3Okc,OjNyNkGzO\|Y9N2F-
HeLa	M2rtWGZ2dmO2aX;uJIF{e2G7		MnqwNlAhdWmwcx?=	MnjNTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJGhmVGFiY3XscJMhfXOrbneg[ox2d3JiZHWgUJl{KGG\|IIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDJyIH3pcpMh[nlibXnjdo9xdGG2ZTDzdIVkfHKxZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyIE2gPE4xOiEQvF2u	NFm1cHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3PCd-MkewOlA4PjR:L3G+
MGC803	M3zHeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnfpO\|IhcHK\|	M4f2cWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1ISzhyMzDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RiZInlJJJm\HWldHnvckBie3OjeTygS2k6OCB;IEiuPUDPxE1w	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MUO3Okc,OjNyNkGzO\|Y9N2F-
K562	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUTkOHdPPDhiaILz	NIe5OnNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IEmuN\|Ih\|ryPLh?=	NIjPOYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[yPVY{OCd-Mki2Nlk3OzB:L3G+
SMMC7721	MmTjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NH3hWpU4OiCqcoO=	MVHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTUW1EPzd{MTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RiZInlJJJm\HWldHnvckBie3OjeTygS2k6OCB;IEGxJO69VS5?	M3vIfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
HeLa	MoS1SpVv[3Srb36gZZN{[Xl?		MXWyOEB1dyB2ODDodpM>	M3nBd2lvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBJ\UyjIHPlcIx{KHW\|aX7nJGJw[y2OeYOoRWMqNUGPQzDhd{B{fWK\|dILheIUh[W[2ZYKgNlQhfG9iNEigbJJ{KGK7IIPw[YN1em:obIXvdo9u\XS{eTygTWM2OCB;IEGxMlE5KM7:TT6=	M{W3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUm2N\|czLz5{Nkm5OlM4OjxxYU6=
HeLa	MlSySpVv[3Srb36gZZN{[Xl?			MmnDTY5pcWKrdHnvckBw\iCKRFHDJIlvKEinTHGgZ4VtdHNuIFnDOVAhRSBzMj61PFkzKM7:TT6=	NVfibWg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NFY{PzBpPkG3OlA3OzdyPD;hQi=>
SKHEP1	NE\L[2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmHRO\|IhcHK\|	M{\pSWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMUEWSMTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RiZInlJJJm\HWldHnvckBie3OjeTygS2k6OCB;IEGzJO69VS5?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MUO3Okc,OjNyNkGzO\|Y9N2F-
A549	M1TU[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXzMZWhIPDhiaILz	NHfGc4FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IEG4MlM4KM7:TT6=	MnvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4Mkm2N\|AoRjJ6NkK5OlMxRC:jPh?=
PC3	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlHYOFghcHK\|	M4X2TmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSBzOT6wPUDPxE1w	NIS0S4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[yPVY{OCd-Mki2Nlk3OzB:L3G+
HeLa	NH;vRY5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3nS[lQ5KGi{cx?=	NEHOR5ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IEG5MlI1KM7:TT6=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ{OU[zNEc,Ojh4Mkm2N\|A9N2F-
MCF7	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NH7jcmY1QCCqcoO=	NVzQS2xZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTCxPU4zPiEQvF2u	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ{OU[zNEc,Ojh4Mkm2N\|A9N2F-
HCT116	MmizRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWq0PEBpenN?	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMkeuOFch\|ryPLh?=	NIPObXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEewNVMxOSd-MUi3NFE{ODF:L3G+
U251	MmTVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYP0d3g3OiCmYYnz	MnvpS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWVI2OSClZXzsd{Bi\nSncjCyJIRigXNiYomgUXRVKGG\|c3H5MEBVT0liPTC0NEDPxE1w	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2MUO5OEc,OjJ3NEGzPVQ9N2F-
HEK293 STF	MmjmSpVv[3Srb36gZZN{[Xl?		Mn3CNlQhcHK\|	MkTyRYN1cX[jdHnvckBw\iCvb4Xz[UBYdnR\|YTDzbYdv[Wyrbneg[ZhxemW\|c3XkJIlvKEiHS{K5N{BUXEZiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6geJJidnOlcnnweIlwdmGuIHHjeIl3cXS7IHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUu[mG\|ZXSgcIFkfGG2ZTDk[Yh6\HKxZ3XuZZNmKGG\|c3H5Mi=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB{Mk[3OUc,OTlyMkK2O\|U9N2F-
U937	NVT0VGI5TnWwY4Tpc44h[XO\|YYm=	MoPYOUB2VQ>?	NWHvelhnOjRiaILz	NUf5NmZ6UW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvckBqdiCXOUO3JINmdGy\|IHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcz6=	NG\ITFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S0O\|c2OCd-MUe0OFc4PTB:L3G+
U937	M4jaNGZ2dmO2aX;uJIF{e2G7			MXrJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNzIHnuJHU6OzdiY3XscJMh[nliaX3teY5weHKnY3nwbZRifGmxbjDhd5NigS5?	M37rUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ixNlM5Lz5zOEO4NVI{QDxxYU6=
U937	MVvGeY5kfGmxbjDhd5NigQ>?			MkjXTY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiaInw[ZJi[2W2eXzheIlwdiCrbjDoeY1idiCXOUO3JINmdGy\|Lh?=	NWLwN2tZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPFEzOzhpPkG4N\|gyOjN6PD;hQi=>
U937	M2\zZ2Z2dmO2aX;uJIF{e2G7			NUTYUHcyUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOEBqdiCXOUO3JINmdGy\|IHL5JIludXWwb4Dy[YNqeGm2YYTpc44h[XO\|YYmu	NVHFW5VuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPFEzOzhpPkG4N\|gyOjN6PD;hQi=>
U937	NGHQZ3ZHfW6ldHnvckBie3OjeR?=			NGfuVHhKdmS3Y4Tpc44hd2ZiZ4LhcpVtd2O7dHnjJIRq\m[ncnXueIlifGmxbjDpckBpfW2jbjDVPVM4KGOnbHzzMi=>	M3j2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ixNlM5Lz5zOEO4NVI{QDxxYU6=
HCT116	MV7GeY5kfGmxbjDhd5NigQ>?	MkTiNVAhfU1?	Ml7aNlQhcHK\|	MV7Jcohq[mm2aX;uJI9nKEiGQVOxJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcHmyZYLhZ4V1gWyjdHnvckBw\iCqaYP0c45mKEh\|IHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOu	MmLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NUKyNlYoRjJyNEWyNlI3RC:jPh?=
NB4	MWDD[YxtKGO7Y3zlJIFzemW\|dDDhd5NigQ>?	Ml75OUB2VQ>?	M1LnZ\|I1KGi{cx?=	NF6wXGJE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBPSjRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZYNkfW23bHH0bY9vKGG2IIDy[U1IOSCyaHHz[UBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDGRWNUKGGwYXz5d4l{Ng>?	NX74UG1nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0PVE1PDBpPkKwOFkyPDRyPD;hQi=>
NB4	NFHUOpZHfW6ldHnvckBie3OjeR?=	NH3vU5k2KHWP	Mle2NlQhcHK\|	MX7JcoR2[3Srb36gc4YheDJzV1HGNU9EUVBzIHX4dJJme3Orb36gbY4hcHWvYX6gUmI1KGOnbHzzJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{4>	MlnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2OUG0OFAoRjJyNEmxOFQxRC:jPh?=
epithelial cells	MkXXSpVv[3Srb36gZZN{[Xl?	M1fyS\|EhfU1?	M160N\|QtKDZuIHHu[EA5KGSjeYO=	NFvqXW9KdmirYnn0bY9vKG:oIFjERWM4KGmwIHj1cYFvKGixbX;6fYdwfXNiRnTlcJRiPTB6IIDybY1ienliYoLvcoNpcWGuIHXwbZRp\WyrYXygZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4he2ixcoSgZ4lz[3WrdDDjeZJz\W62czDheEAyKHWPIH\vdkA1NCB4LDDhcoQhQCCmYYnzJJJmdGG2aY\lJJRwKGOxboTyc4wv	NX7IRYtRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlY4QDlpPkG5PVY3Pzh7PD;hQi=>
Hela	MnTMSpVv[3Srb36gZZN{[Xl?	MoXBNE43KHWP	MXGxOkBpenN?	M{TrRWlvcGmkaYTpc44hd2ZiSFTBR\|YhcW5iaIXtZY4hUGWuYTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB1d3SjbDDsfZNqdmViYXPleJlt[XSrb36gZZQhOC54IIXNJIFnfGW{IEG2JIhzeyCkeTDpcY12dm:obIXvdoV{[2WwY3WgcYlkem:\|Y3;wfU4>	MnXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4OU[5OVYoRjJzNkm2PVU3RC:jPh?=
U937	NGrvTZdE\WyuIHP5Z4xmKGG{cnXzeEBie3OjeR?=	NGjrT4U2KHWP	M17rN\|MxKGi{cx?=	M2rrdWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHU6OzdiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNmKGG2IEWgeW0h[W[2ZYKgN\|AhcHK\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpkv	Mn[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MUW2OFcoRjJzMkG1OlQ4RC:jPh?=
epithelial cells	MlvmSpVv[3Srb36gZZN{[Xl?	MW[1JJVO		NGi1VIVKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4heHKrbXHyfUBjem:wY3jpZYwh\XCrdHjlcIlidCClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9vKGG2IEWgeW0v	M1KyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
NB4	M1nmcmZ2dmO2aX;uJIF{e2G7	MU[1JJVO	NVvDPHhpOjRiaILz	MmTTTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJG5DPCClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIFk\XS7bHH0bY9vKGG2IEWgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqey5?	M3;xU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEmxOFQxLz5{MES5NVQ1ODxxYU6=
C127-LT	NH;BRYpHfW6ldHnvckBie3OjeR?=	NVva[pNNOSC3TR?=	NGHtfZQzPCCqcoO=	NIfsPG1KdmirYnn0bY9vKG:oIFjERWMhcW5ibX;1d4UhSzF{Nz3MWEBk\WyuczDhd5Nme3OnZDDhd{Bi[3SrdnH0bY9vKG:oIFXHSnAh\XiycnXzd4lwdiCjdDCxJJVOKGGodHXyJFI1KGi{czDifUBndHWxcnXzZ4Vv[2VibXnjdo9{[2:yeT6=	NV:yfYJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PVY{PzJpPkK2PVk3Ozd{PD;hQi=>
C127-LT	M1\k[2Z2dmO2aX;uJIF{e2G7	NH3CUHoyOCC3TR?=	NGf0epczPCCqcoO=	NUjPcVM4UW6qaXLpeIlwdiCxZjDISGFEKGmwIH3veZNmKENzMketUHQh[2WubIOgZZN{\XO\|ZXSgZZMh[WO2aY\heIlwdiCxZjDFS2ZRKGW6cILld5Nqd25iYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KG[udX;y[ZNk\W6lZTDtbYNzd3Olb4D5Mi=>	Ml;WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OU[zO\|IoRjJ4OUm2N\|czRC:jPh?=
HCT116	M1PtN2Z2dmO2aX;uJIF{e2G7	M3ThS\|ExKHWP	M2fadVI1KGi{cx?=	Mo\XTY5pcWKrdHnvckBw\iCKRFHDNkBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgbJlx\XKjY3X0fYxifGmxbjDv[kBpcXO2b37lJGg{KGG2IEGwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNw	M2jBUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{KxNlE2Lz5{MkOyNVIyPTxxYU6=
HCT116	MmXkSpVv[3Srb36gZZN{[Xl?	NIn0cm8yOCC3TR?=	NFyzeGwzPCCqcoO=	NXHPVHdwUW6qaXLpeIlwdiCxZjDISGFEOSCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCqaYP0c45mKEh\|IHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOu	Mlr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|MkGyNVUoRjJ{M{KxNlE2RC:jPh?=
TC32	MWTxTHRUKGG\|c3H5			MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtey5?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	NWi1Wll4eUiWUzDhd5NigQ>?			MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|Lh?=	M2PTWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	NV\3Tm1EeUiWUzDhd5NigQ>?			NVPNblhseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIOu	M{C1UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	M1TQW5FJXFNiYYPzZZk>			NIjCeY9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucz6=	NX\WSpBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	NGC5e2VyUFSVIHHzd4F6			MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|Lh?=	NVnvSVBIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MmXvdWhVWyCjc4PhfS=>			NEj2eo1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIOu	NH;XRZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	NEm2NYRyUFSVIHHzd4F6			MnS0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{Ng>?	Ml\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	M{nyUZFJXFNiYYPzZZk>			NW\CPIw1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJMv	NHfMO\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MmLIdWhVWyCjc4PhfS=>			NUO0elh{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzzMi=>	MmXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NF2w[mhyUFSVIHHzd4F6			M4LIcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucz6=	M4CyR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	M2L4NZFJXFNiYYPzZZk>			NV;J[mFjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsd{4>	NGXnWnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NWTPOml[eUiWUzDhd5NigQ>?			M2LPb5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIOu	M4LZRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
fibroblast cells	MX7xTHRUKGG\|c3H5			NHfFUmpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiY3;ueJJwdCCKaDD3bYxlKHS7cHWg[oljem:kbHHzeEBk\Wyucz6=	NGXxZms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	MkjWdWhVWyCjc4PhfS=>			NHfPcGtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtey5?	NHjtXmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	M4DUNZFJXFNiYYPzZZk>			MnyydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgSGFQYSClZXzsd{4>	NHG3UIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MnvydWhVWyCjc4PhfS=>			NWrsNYY1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIOu	M{DiUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	MX7xTHRUKGG\|c3H5			MkjpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtey5?	MljHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	M1rI[ZFJXFNiYYPzZZk>			Mm\IdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHNw	NVHPRWRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	M3KwZZFJXFNiYYPzZZk>			NX;nZ49DeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteylw	MofmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	MVHxTHRUKGG\|c3H5			NEHwWZhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1\|NzDj[Yxtey5?	NX2wVnVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	MknudWhVWyCjc4PhfS=>			M{P4W5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{Ng>?	NVXmOG1XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	NF3L[mVyUFSVIHHzd4F6			NEToS4NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{Ng>?	NFvLOYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
U-2 OS	MV\xTHRUKGG\|c3H5			NUXYR4tteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|Lh?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NUi1cYtueUiWUzDhd5NigQ>?			M2nPRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG9JWy13MDDj[Yxtey5?	MonuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	M{HHSpFJXFNiYYPzZZk>			NV;YfJJVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtey5?	NXLFPVJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	NHT1PYlyUFSVIHHzd4F6			NYq3VZFPeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJMv	NFLZS4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	M4LOZZFJXFNiYYPzZZk>			MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucz6=	M4jkW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NHL1[otyUFSVIHHzd4F6			M{XPUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzzMi=>	NHe4flM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	NGnueG1yUFSVIHHzd4F6			NXTXUFQ5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJMv	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NYLKW49beUiWUzDhd5NigQ>?			NWjRRnpxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzzMi=>	M2H1XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	MUPxTHRUKGG\|c3H5			NXLWUnE3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIOu	MoC4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	NV7NNFJKeUiWUzDhd5NigQ>?			MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORlE3PDNiY3XscJMv	MmnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	M4H6W5FJXFNiYYPzZZk>			MWPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{Ng>?	MmW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MXjxTHRUKGG\|c3H5			MoridWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtey5?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	MlPjdWhVWyCjc4PhfS=>			NHfudlVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{Ng>?	NH\FdVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	MWnxTHRUKGG\|c3H5			MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFE5KGOnbHzzMi=>	M2DwV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	NUjvR5R6eUiWUzDhd5NigQ>?			MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTZY9{NTJiY3XscJMv	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
HeLa	MWTGeY5kfGmxbjDhd5NigQ>?	Ml[1NUB2VQ>?	MmfWOkBpenN?	NFHtOnFKdmirYnn0bY9vKG:oIFjERWMyN0iGQVOyM2hFSUN\|IHnuJIh2dWGwIFjlUIEh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBi[2W2eXytbIl{fG:wZTDIOEBt\X[nbIOgZZQhOSC3TTDh[pRmeiB4IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOu	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd6N{K2Nkc,Ojl5OEeyOlI9N2F-
MV4-11	MkG5RZBweHSxc3nzJIF{e2G7	MXi1JJVO	NYL5TJp5OjRidH:gOFghcHK\|	NVnST2VvUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNWlQuOTFiY3XscJMh[XRiNTD1UUBi\nSncjCyOEB1dyB2ODDodpMh[nliQX7u[ZhqdiCYLWDJJJN1[WmwaX7nJIJie2WmIH\sc5ch[3m2b33leJJ6Ng>?	NHr1RWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezPFk2Oyd-Mkm3N\|g6PTN:L3G+
MV4-11	MULGeY5kfGmxbjDhd5NigQ>?	M3;vZlIxOCCwTR?=	M4DoRVI1KGi{cx?=	NFW5[2xKdmirYnn0bY9vKG:oIHPsZZN{KDFiSFTBR{BqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbJlx\XKjY3X0fYxifGmxbjDv[kBpcXO2b37lJGg{KGG2IEKwNEBvVSCjZoTldkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|Lh?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|OEm1N{c,Ojl5M{i5OVM9N2F-
HL60	NUDHXWZoSXCxcITvd4l{KGG\|c3H5	MoTOOUB2VQ>?	M1nrVVQ5KGi{cx?=	NXHK[VZrUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIUFYxKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIIDyc4Nie3Cjc3WtN{Bt\X[nbDDheEA2KHWPIHHmeIVzKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOu	NGfTNo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESxOVAxQSd-Mki0NVUxODl:L3G+
HL60	NVn0bmh1SXCxcITvd4l{KGG\|c3H5	NHH4NHY2KHWP	MXO0PEBpenN?	MWrJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[2ynYY\l[EBk[XOyYYPlMVMhdGW4ZXygZZQhPSC3TTDh[pRmeiB2ODDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nzMi=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzNUCwPUc,Ojh2MUWwNFk9N2F-
HL60	MoniRZBweHSxc3nzJIF{e2G7	MmLNOUB2VQ>?	NGjGWYE1QCCqcoO=	MVjJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[2ynYY\l[EBRSVKSIHzleoVtKGG2IEWgeW0h[W[2ZYKgOFghcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqey5?	MlG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MUWwNFkoRjJ6NEG1NFA6RC:jPh?=
MV4-11	M13WXWNmdGxiY4njcIUh[XK{ZYP0JIF{e2G7	NHT4R2M2KHWP	MnPoNlQhcHK\|	NETheXZE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[UBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndILpZ{Bu\XSqb3Su	MlrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3OEm0OFEoRjJ7NUi5OFQyRC:jPh?=
HEL	MYTD[YxtKGO7Y3zlJIFzemW\|dDDhd5NigQ>?	NUS3dZJxPSC3TR?=	NHLGfpkzPCCqcoO=	M{TiXmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGhGVCClZXzsd{BifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndILpZ{Bu\XSqb3Su	M1XWV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUi5OFQyLz5{OUW4PVQ1OTxxYU6=
Jurkat	Ml\2R4VtdCCleXPs[UBienKnc4SgZZN{[Xl?	NFnud2E2KHWP	MY[yOEBpenN?	NU\mSYhFS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUnW{a3H0JINmdGy\|IHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[oxwfyCleYTvcYV1emmlIH3leIhw\C5?	NEPnPG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW4PVQ1OSd-Mkm1PFk1PDF:L3G+
MV4-11	NHfhcGlHfW6ldHnvckBie3OjeR?=	NESxTXM2KHWP	MUSyOEBpenN?	M2ewZWlvcGmkaYTpc44hd2ZiY3zhd5MhOSCKRFHDJIlvKGi3bXHuJG1XPC1zMTDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBpgXCncnHj[ZR6dGG2aX;uJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBu\XSqb3Su	NUfRUmk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1PFk1PDFpPkK5OVg6PDRzPD;hQi=>
LNCAP	Mn3GSpVv[3Srb36gZZN{[Xl?	NF\mWpgyOCC3TR?=	NIjrV3kzPCCqcoO=	NX3PflRjUW6qaXLpeIlwdiCxZjDISGFEPiCrbjDoeY1idiCOTlPBVEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFTIWE1qdmS3Y3XkJIFteGijLYT1ZpVtcW5iZHXhZ4V1gWyjdHnvckBjgSCvZXHzeZJqdmdiaX7jdoVie2ViaX6gZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbjDheEAyOCC3TTDt[YF{fXKnZDDh[pRmeiB{NDDodpMhemWuYYTpeoUhfG9iY3;ueJJwdC5?	M{DQd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{G3OVQ1Lz5{N{exO\|U1PDxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	- Collapse Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	- Collapse Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	SNDX-275
Smiles	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04708470	Recruiting	Drug: Bintrafusp Alfa\|Drug: NHS-IL12\|Drug: Entinostat	Cancer\|Solid Tumor\|Metastatic Checkpoint Refractory HPV Associated Malignancies\|Microsatellite Stable Colon Cancer (MSS)	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	September 7 2021	Phase 1\|Phase 2
NCT03829930	Terminated	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Terminated	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)